MedTrace Logo

A Study of ResCure™ to Treat COVID-19 Infection

NCT04395716 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2021-04-08

No results posted yet for this study

Summary

This is a Phase I open-label interventional study which will test the efficacy of ResCure™ in the treatment of patients with COVID-19 infection.

Conditions

  • COVID
  • Covid-19
  • Corona Virus Infection
  • Sars-CoV2
  • Coronavirus-19
  • SARS Pneumonia
  • SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere

Interventions

BIOLOGICAL

ResCure™

Patients will be treated with nebulized ResCure™

Sponsors & Collaborators

  • Rinati Skin, LLC

    collaborator UNKNOWN

  • ProgenaBiome

    lead OTHER

Principal Investigators

  • Sabine Hazan, MD · ProgenaBiome

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-31
Primary Completion
2021-06-30
Completion
2021-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04395716 on ClinicalTrials.gov